X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Maiweijian (denosumab) is a fully human recombinant anti-RANKL monoclonal antibody, which is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: Maiweijian
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
9MW2821 is a site-specific conjugated novel Nectin-4-targeting ADC, which is being evaluated for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
Lead Product(s): 9MW2821
Therapeutic Area: Oncology Product Name: 9MW2821
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
MW032 (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia. It is a RANK ligand inhibitor, which is being evaluated for treament of bone metastases from solid tumors.
Lead Product(s): Denosumab
Therapeutic Area: Oncology Product Name: MW032
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
7MW3711 is a novel antibody-drug conjugate targeting B7-H3, which is a member of the B7 ligand family and is overexpressed in most cancer type. It is being evaluated for the treatment of advanced malignant solid tumor.
Lead Product(s): 7MW3711
Therapeutic Area: Oncology Product Name: 7MW3711
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
9MW3011 is an anti-TMPRSS6 antibody which can upregulate the level of hepcidin expressed by hepatocytes through specific binding. It is being evaluated for the treatment of β-thalassemia and polycythemia vera.
Lead Product(s): 9MW3011
Therapeutic Area: Genetic Disease Product Name: DISC-3405
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Disc medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
8MW0511 is a G-CSF inhibitor, protein drug candidate, which is currently being evaluated for the treatment of adult patients with non-myeloid malignant neoplasms manifested by febrile neutropenia.
Lead Product(s): 8MW0511
Therapeutic Area: Hematology Product Name: 8MW0511
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
9MW2821 is China's first, global second Nectin-4 targeted ADC approved for pivotal clinical study. The multiple ongoing clinical studies include more than 10 different solid tumors, evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity.
Lead Product(s): 9MW2821,Toripalimab
Therapeutic Area: Oncology Product Name: 9MW2821
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
9MW2821 is China's first, global second Nectin-4 targeted ADC, which is investigated in combination with PD-1 inhibitor for the treatment of locally advanced or metastatic urothelial carcinoma.
Lead Product(s): 9MW2821,Undisclosed
Therapeutic Area: Oncology Product Name: 9MW2821
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
9MW3011 is monoclonal antibody which can upregulate the level of hepcidin expressed by hepatocytes through specific binding, inhibit the absorption and release of iron, and lower the serum iron level, thus regulating the iron homeostasis in vivo.
Lead Product(s): 9MW3011
Therapeutic Area: Oncology Product Name: 9MW3011
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
MWTX-003, also known as DISC-3405, is an investigational, anti-TMPRSS6 monoclonal antibody, which is investigated for the treatment of patients with polycythemia vera.
Lead Product(s): DISC-3405
Therapeutic Area: Oncology Product Name: MWTX-003
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Disc medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
